Glucagon-like peptide-1 analog: Difference between revisions

Jump to navigation Jump to search
(New page: '''Glucagon-like peptide-1 analog'''s are a new class of drug for treatment of type 2 diabetes.<ref>http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs ...)
 
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
'''[[Glucagon-like peptide-1]] analog'''s are a new class of [[drug]] for treatment of [[type 2 diabetes]].<ref>http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs Other Than Exenatide" </ref> 
{{SI}}
{{CMG}}


One of their advantages is that they have a lower risk of causing [[hypoglycemia]].


Licenced : [[exenatide]] (2005)


Under investigation : [[liraglutide]], [[albiglutide]], [[taspoglutide]]
==Overview==
 
'''[[Glucagon-like peptide-1]] analog'''s are a new class of [[drug]] for treatment of [[type 2 diabetes]]. <ref>http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs Other Than Exenatide" </ref> One of their advantages is that they have a lower risk of causing [[hypoglycemia]].
 
===Licenced:===
 
* [[exenatide]] (2005)
 
===Under investigation: ===
 
* albiglutide
* taspoglutide


==References==
==References==
{{reflist}}
{{reflist|2}}


{{Oral hypoglycemics and insulin analogs}}
{{Oral hypoglycemics and insulin analogs}}
[[Category:Hormones]]
[[Category:Drugs]]

Latest revision as of 17:52, 4 September 2012

WikiDoc Resources for Glucagon-like peptide-1 analog

Articles

Most recent articles on Glucagon-like peptide-1 analog

Most cited articles on Glucagon-like peptide-1 analog

Review articles on Glucagon-like peptide-1 analog

Articles on Glucagon-like peptide-1 analog in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Glucagon-like peptide-1 analog

Images of Glucagon-like peptide-1 analog

Photos of Glucagon-like peptide-1 analog

Podcasts & MP3s on Glucagon-like peptide-1 analog

Videos on Glucagon-like peptide-1 analog

Evidence Based Medicine

Cochrane Collaboration on Glucagon-like peptide-1 analog

Bandolier on Glucagon-like peptide-1 analog

TRIP on Glucagon-like peptide-1 analog

Clinical Trials

Ongoing Trials on Glucagon-like peptide-1 analog at Clinical Trials.gov

Trial results on Glucagon-like peptide-1 analog

Clinical Trials on Glucagon-like peptide-1 analog at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Glucagon-like peptide-1 analog

NICE Guidance on Glucagon-like peptide-1 analog

NHS PRODIGY Guidance

FDA on Glucagon-like peptide-1 analog

CDC on Glucagon-like peptide-1 analog

Books

Books on Glucagon-like peptide-1 analog

News

Glucagon-like peptide-1 analog in the news

Be alerted to news on Glucagon-like peptide-1 analog

News trends on Glucagon-like peptide-1 analog

Commentary

Blogs on Glucagon-like peptide-1 analog

Definitions

Definitions of Glucagon-like peptide-1 analog

Patient Resources / Community

Patient resources on Glucagon-like peptide-1 analog

Discussion groups on Glucagon-like peptide-1 analog

Patient Handouts on Glucagon-like peptide-1 analog

Directions to Hospitals Treating Glucagon-like peptide-1 analog

Risk calculators and risk factors for Glucagon-like peptide-1 analog

Healthcare Provider Resources

Symptoms of Glucagon-like peptide-1 analog

Causes & Risk Factors for Glucagon-like peptide-1 analog

Diagnostic studies for Glucagon-like peptide-1 analog

Treatment of Glucagon-like peptide-1 analog

Continuing Medical Education (CME)

CME Programs on Glucagon-like peptide-1 analog

International

Glucagon-like peptide-1 analog en Espanol

Glucagon-like peptide-1 analog en Francais

Business

Glucagon-like peptide-1 analog in the Marketplace

Patents on Glucagon-like peptide-1 analog

Experimental / Informatics

List of terms related to Glucagon-like peptide-1 analog

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes. [1] One of their advantages is that they have a lower risk of causing hypoglycemia.

Licenced:

Under investigation:

  • albiglutide
  • taspoglutide

References

  1. http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs Other Than Exenatide"